Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy?
作者信息
Piaserico S, Gisondi P, Cazzaniga S, Girolomoni G, Calzavara-Pinton P G, Naldi L
机构信息
Department of Medicine, Section of Dermatology, University of Padua, Padua, Italy.
Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
出版信息
J Eur Acad Dermatol Venereol. 2021 Jun;35(6):e355-e357. doi: 10.1111/jdv.17175. Epub 2021 Mar 5.
Abstract
摘要
相似文献
1
Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy?对于候选生物治疗的银屑病患者，是否需要进行新型冠状病毒2型（SARS-CoV-2）筛查检测？
J Eur Acad Dermatol Venereol. 2021 Jun;35(6):e355-e357. doi: 10.1111/jdv.17175. Epub 2021 Mar 5.
2
Biologic therapy for psoriasis during the COVID-19 outbreak: The choice is to weigh risks and benefits.2019冠状病毒病疫情期间银屑病的生物治疗：选择需权衡风险与获益。
Dermatol Ther. 2020 Jul;33(4):e13490. doi: 10.1111/dth.13490. Epub 2020 May 20.
3
The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy.生物制剂治疗的银屑病患者中 SARS-CoV-2 感染的流行率和 COVID-19 病程的严重程度。
J Dermatolog Treat. 2022 May;33(3):1581-1584. doi: 10.1080/09546634.2020.1861177. Epub 2020 Dec 22.
4
COVID-19 and psoriasis: biologic treatment and challenges.COVID-19 与银屑病：生物治疗及挑战
J Dermatolog Treat. 2022 Mar;33(2):699-703. doi: 10.1080/09546634.2020.1789051. Epub 2020 Jul 6.
5
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination.
Br J Dermatol. 2023 Oct 25;189(5):635-637. doi: 10.1093/bjd/ljad242.
6
Incidence and prognosis of COVID-19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study.接受生物治疗的银屑病患者中新冠病毒病的发病率和预后：一项多中心回顾性队列研究
J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e485-e487. doi: 10.1111/jdv.17279. Epub 2021 May 1.
7
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study.意大利 COVID-19 大流行期间接受生物制剂治疗的慢性斑块型银屑病患者的特征：来自 PSO-BIO-COVID 观察性研究的风险分析。
Expert Opin Biol Ther. 2021 Feb;21(2):271-277. doi: 10.1080/14712598.2021.1853698. Epub 2021 Jan 13.
8
Psoriasis, COVID-19, and acute respiratory distress syndrome: Focusing on the risk of concomitant biological treatment.银屑病、新冠病毒肺炎与急性呼吸窘迫综合征：关注联合生物治疗的风险
Dermatol Ther. 2020 Jul;33(4):e13706. doi: 10.1111/dth.13706. Epub 2020 Jun 19.
9
Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID).COVID-19大流行期间接受传统全身治疗、生物治疗或局部治疗的银屑病患者中SARS-CoV-2感染的患病率、风险和严重程度：一项横断面队列研究（PsoCOVID）
J Dermatolog Treat. 2023 Dec;34(1):2161297. doi: 10.1080/09546634.2022.2161297.
10
SARS-CoV-2 serology in patients on biological therapy or apremilast for psoriasis: a study of 93 patients in the Italian red zone.接受生物疗法或阿普米拉斯治疗的银屑病患者的新型冠状病毒2型血清学研究：意大利疫情重灾区93例患者的研究
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e86-e88. doi: 10.1111/jdv.17721. Epub 2021 Oct 14.
引用本文的文献
1
Clinical Dermatology and COVID-19 Pandemic: Narrative Review.临床皮肤病学与新冠疫情：叙述性综述
Indian J Dermatol. 2021 May-Jun;66(3):246-255. doi: 10.4103/ijd.ijd_463_21.
本文引用的文献
1
Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome.定义与疾病严重程度和结局相关的 SARS-CoV-2 感染后抗体反应的特征和持续时间。
Sci Immunol. 2020 Dec 7;5(54). doi: 10.1126/sciimmunol.abe0240.
2
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience.接受生物治疗的银屑病患者因 COVID-19 住院和死亡的发生率：意大利北部的经验。
J Allergy Clin Immunol. 2021 Feb;147(2):558-560.e1. doi: 10.1016/j.jaci.2020.10.032. Epub 2020 Nov 5.
3
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.自身免疫性疾病患者 COVID-19 的患病率和临床结局：系统评价和荟萃分析。
Ann Rheum Dis. 2021 Mar;80(3):384-391. doi: 10.1136/annrheumdis-2020-218946. Epub 2020 Oct 13.
4
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.国家银屑病基金会 COVID-19 工作组关于大流行期间银屑病管理的指南：第 1 版。
J Am Acad Dermatol. 2020 Dec;83(6):1704-1716. doi: 10.1016/j.jaad.2020.09.001. Epub 2020 Sep 4.
5
Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic.COVID-19 大流行期间需要住院治疗的 IBD 患者的护理。
J Crohns Colitis. 2020 Oct 21;14(14 Suppl 3):S774-S779. doi: 10.1093/ecco-jcc/jjaa150.
6
Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce.炎症性肠病在 COVID-19 爆发期间的管理：来自 ECCO-COVID 工作组的十大注意事项。
J Crohns Colitis. 2020 Oct 21;14(14 Suppl 3):S798-S806. doi: 10.1093/ecco-jcc/jjaa160.
7
Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel.在 COVID-19 大流行背景下对英国胃肠病学会关于急性重度 UC 管理指南的适应性调整：一个 RAND 适宜性小组。
Gut. 2020 Oct;69(10):1769-1777. doi: 10.1136/gutjnl-2020-321927. Epub 2020 Jun 8.
8
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2.EULAR 临时推荐意见：在 SARS-CoV-2 背景下管理风湿和肌肉骨骼疾病。
Ann Rheum Dis. 2020 Jul;79(7):851-858. doi: 10.1136/annrheumdis-2020-217877. Epub 2020 Jun 5.
9
Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak.在疫情爆发时对炎症性肠病（IBD）患者进行生物治疗前筛查活动性新冠病毒感染和免疫状态。
Dig Liver Dis. 2020 Jun;52(6):604-605. doi: 10.1016/j.dld.2020.04.004. Epub 2020 Apr 10.
10
Virological assessment of hospitalized patients with COVID-2019.住院 COVID-19 患者的病毒学评估。
Nature. 2020 May;581(7809):465-469. doi: 10.1038/s41586-020-2196-x. Epub 2020 Apr 1.
Zotero 插件